The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.
 
Assuntina Gesualda Sacco
Honoraria - Onclive
Research Funding - inVentiv Health (Inst); Merck (Inst); Pfizer/EMD Serono (Inst)
 
Ruifeng Chen
No Relationships to Disclose
 
Debanjali Ghosh
No Relationships to Disclose
 
Deborah J.L. Wong
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Bristol-Myers Squibb; Genentech/Roche; Kura Oncology; Merck Serono; Merck Sharp & Dohme; Regeneron
 
Francis P. Worden
Consulting or Advisory Role - Bristol-Myers Squibb; Loxo; Merck
Research Funding - Bristol-Myers Squibb; Eisai (Inst); Loxo; Merck (Inst); Pfizer (Inst); Progenics
 
Douglas Adkins
Consulting or Advisory Role - Celgene; Lilly; Loxo; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cellceutix (Inst); Celldex (Inst); Enzychem Lifesciences (Inst); Exelixis (Inst); Gliknik (Inst); Innate Pharma (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst)
 
Emily Pittman
No Relationships to Disclose
 
Karen Messer
No Relationships to Disclose
 
Kathryn A. Gold
Honoraria - Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Regeneron; Takeda
Speakers' Bureau - Takeda
Research Funding - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Pharmacyclics; Roche/Genentech
 
Gregory A. Daniels
Honoraria - Sanofi/Regeneron
Consulting or Advisory Role - Sanofi/Regeneron
Speakers' Bureau - Array BioPharma; Regeneron; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Viralytics (Inst)
 
Paul Swiecicki
Research Funding - Ascentage Pharma Group; Pfizer
 
Brian Sutton
No Relationships to Disclose
 
Amanda Natsuhara
No Relationships to Disclose
 
Ezra E.W. Cohen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Human Longevity, Inc; Incyte; Mavu Pharmaceutical; Merck; Nanobiotix; Pfizer